NCT03956888View on ClinicalTrials.gov

The Anti-oxidant Effects of N-Acetylcysteine in Chronic Obstructive Pulmonary Disease (COPD)

PHASE3CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

May 1, 2019

Primary Completion Date

December 30, 2023

Study Completion Date

December 30, 2024

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
DRUG

N-acetylcysteine

All COPD patients will be treated with N-acetylcysteine at the dose of 1200 mg per day (600 mg three times a day) for 4 weeks in addition to their current COPD medications without other mucolytic agents

Trial Locations (1)

10700

Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok

All Listed Sponsors
lead

Siriraj Hospital

OTHER

NCT03956888 - The Anti-oxidant Effects of N-Acetylcysteine in Chronic Obstructive Pulmonary Disease (COPD) | Biotech Hunter | Biotech Hunter